Anti-HLA-G/CD3 Bispecific Antibody RO7515629

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific antibody targeting the tumor-associated antigen (TAA) histocompatibility antigen, class I, G (human leukocyte antigen G; HLA-G) and the CD3 antigen found on T-lymphocytes, with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon administration, the anti-HLA-G/CD3 bispecific antibody RO7515629 targets and binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and HLA-G found on HLA-G-expressing tumor cells. This activates and redirects CTLs to HLA-G-expressing tumor cells, which results in the CTL-mediated cell death of HLA-G-expressing tumor cells. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor cell types and plays a key role in cancer immune evasion. It inhibits the immune responses by binding to its inhibitory receptors on a variety of immune cells, such as natural killer cells (NKs), T- and B-lymphocytes, and dendritic cells (DCs).

**Synonyms:** - Anti-HLA-G T-cell Engager RO7515629 - CD3-binding T-cell Engager RO7515629 - HLA-G TCB RO7515629 - HLA-G-TCB RG6353 - RG 6353 - RG-6353 - RG6353 - RO 7515629 - RO-7515629 - RO7515629 - T-cell Bispecific Antibody RO7515629 - TCB RO7515629 - TCE RO7515629